Endologix (NASDAQ:ELGX) posted its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.12, Bloomberg Earnings reports. Endologix had a negative net margin of 41.60% and a negative return on equity of 52.18%. The firm had revenue of $44.00 million for the quarter, compared to the consensus estimate of $44.91 million. During the same period in the prior year, the firm posted ($0.30) EPS. The firm’s revenue was down 7.3% compared to the same quarter last year.
Shares of Endologix (NASDAQ:ELGX) traded up $0.05 during trading hours on Wednesday, hitting $4.38. 598,847 shares of the company’s stock were exchanged, compared to its average volume of 792,341. The firm has a market capitalization of $373.87, a PE ratio of -4.71 and a beta of 0.42. Endologix has a 52 week low of $3.77 and a 52 week high of $7.66. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61.
ELGX has been the topic of a number of research analyst reports. JPMorgan Chase & Co. downgraded shares of Endologix from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 2nd. Royal Bank of Canada reduced their price objective on shares of Endologix from $5.00 to $4.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 8th. BidaskClub downgraded shares of Endologix from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. Stifel Nicolaus reduced their price objective on shares of Endologix from $6.00 to $5.50 and set a “hold” rating on the stock in a research note on Wednesday, November 8th. Finally, ValuEngine downgraded shares of Endologix from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $5.41.
TRADEMARK VIOLATION NOTICE: “Endologix (ELGX) Issues Earnings Results” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/21/endologix-elgx-issues-earnings-results.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.